27 research outputs found
Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
The effect of interrupted anti-retroviral treatment on the reconstitution of memory and naive T cells during tuberculosis treatment in HIV patients with active pulmonary tuberculosis
Background: The reconstitution of cellular immune components contributes to clinical outcome of HIV and Mycobacterium tuberculosis (MTB) infection. Interruption of anti-retroviral therapy (ART) could lead to perturbations in reconstitution of T cells in HIV/ tuberculosis (TB) patients. Objectives: To ascertain the effect of interrupted ART on reconstitution of CD4+ and CD8+ T sub-sets in TB patients.Methods: Participants with HIV (CD4>350 cells/μL) and TB were recruited under a larger phase 3 open label randomised controlled clinical trial. The CD45RO and CD62L markers were measured on CD4+ and CD8+ cells by flow cytometry. Samples were analysed at baseline, 3, 6, 12 months.Results: There was a significant increase of naive CD8+ cells (p = 0.003) and a decrease in effector CD8+ cells (p = 0.004) among participants in ART/TB treatment arm during the first 6 months. Withdrawing ART led to naive CD8+ cells reduction (p=0.02) to values close to baseline. An increase of naive CD8+ cells after 6 months of TB treatment in TB alone treatment arm (p=0.01) was observed. A trend towards increment of naive CD4+ sub sets in either treatment arms was observed.Conclusion: Interrupting ART alters CD8+ but not CD4+ sub-sets in patients with less advanced HIV infection and TB.Keywords: Interrupted anti-retroviral treatment, memory and naive T cells, HIV patients, active pulmonary tuberculosis
The effect of interrupted anti-retroviral treatment on the reconstitution of memory and naive T cells during tuberculosis treatment in HIV patients with active pulmonary tuberculosis.
Background: The reconstitution of cellular immune components
contributes to clinical outcome of HIV and Mycobacterium tuberculosis
(MTB) infection. Interruption of anti-retroviral therapy (ART) could
lead to perturbations in reconstitution of T cells in HIV/ tuberculosis
(TB) patients. Objectives: To ascertain the effect of interrupted ART
on reconstitution of CD4+ and CD8+ T sub-sets in TB patients. Methods:
Participants with HIV (CD4>350 cells/\ub5L) and TB were recruited
under a larger phase 3 open label randomised controlled clinical trial.
The CD45RO and CD62L markers were measured on CD4+ and CD8+ cells by
flow cytometry. Samples were analysed at baseline, 3, 6, 12 months.
Results: There was a significant increase of naive CD8+ cells (p =
0.003) and a decrease in effector CD8+ cells (p = 0.004) among
participants in ART/TB treatment arm during the first 6 months.
Withdrawing ART led to naive CD8+ cells reduction (p=0.02) to values
close to baseline. An increase of naive CD8+ cells after 6 months of TB
treatment in TB alone treatment arm (p=0.01) was observed. A trend
towards increment of naive CD4+ sub sets in either treatment arms was
observed. Conclusion: Interrupting ART alters CD8+ but not CD4+
sub-sets in patients with less advanced HIV infection and TB
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria
Background: There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as transmission blocking in African children with acute Plasmodium falciparum and glucose-6-phosphate dehydrogenase deficiency (G6PDd).
Methods: Primaquine pharmacokinetics of age-dosed SLDPQ (shown previously to be gametocytocidal with similar tolerability as placebo) were characterised in falciparum-infected Ugandan and Congolese children aged 6 months to 11 years, treated on admission with standard 3-day dihydroartemisinin-piperaquine or artemether-lumefantrine plus SLDPQ: 6 m–<1 y: 1.25 mg, 1–5 y: 2.5 mg, 6–9 y: 5 mg, 10–11 y: 7.5 mg. LC-MS/MS-measured plasma primaquine and carboxyprimaquine (baseline, 1, 1.5, 2, 4, 8, 12, 24 h) were analysed by noncompartmental analysis. Multivariable linear regression modelled associations between covariates, including cytochrome-P450 2D6 metaboliser status, and outcomes.
Findings: 258 children (median age 5 [interquartile range (IQR) 3–7]) were sampled; 8 (3.1%) with early vomiting were excluded. Primaquine doses of 0.10–0.40 (median 0.21, IQR 0.16–0.25) mg base/kg resulted in primaquine maximum plasma concentrations (Cmax) of 2.3–447 (median 103.0, IQR 72.1–140.0) ng/mL between 1.0 and 8.0 (median 2) hours (Tmax) and median areas under the drug concentration curves (AUC0-last) 730.2 (6 m–<1 y, n = 12), 582.8 (1–5 y, n = 126), 871.1 (6–9 y, n = 80), and 931.0 (10–11 y, n = 32) ng∗h/mL. Median elimination half-live (T½) was 4.7 (IQR 3.8–5.6) hours. Primaquine clearance/kg peaked at 18 months, plateauing at 4 y. Increasing CYP2D6 metaboliser activity score [poor (3/250), intermediate (52/250), normal (150/250), ultrarapid (5/250), indeterminate (40/250)] and baseline haemoglobin were significantly associated with a lower primaquine AUC0-last,which increased with increasing mg/kg dose and age but was independent of the artemisinin treatment used.
Interpretation: Age-dosed SLDPQ resulted in variable primaquine exposure that depended on bodyweight-adjusted dose, age, baseline haemoglobin and CYP2D6 metaboliser status, but not on dihydroartemisinin-piperaquine or artemether-lumefantrine. These data support age-dosed SLDPQ for transmission blocking in sub-Saharan Africa.
Funding: This work was cofunded by the UK Medical Research Council, Wellcome Trust, and UK Aid through the Global Health Trials (grant reference MR/P006973/1). The funders had no role in the study design, execution, and analysis and decisions regarding publication
Response to <it>M. tuberculosis </it>selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Abstract Background Tuberculosis (TB) is the most frequent co-infection in HIV-infected individuals still presenting diagnostic difficulties particularly in developing countries. Recently an assay based on IFN-gamma response to M. tuberculosis RD1 peptides selected by computational analysis was developed whose presence is detected during active TB disease. Objective of this study was to investigate the response to selected RD1 peptides in HIV-1-infected subjects with or without active TB in a country endemic for TB and to evaluate the change of this response over time. Methods 30 HIV-infected individuals were prospectively enrolled, 20 with active TB and 10 without. Among those with TB, 12 were followed over time. IFN-gamma response to selected RD1 peptides was evaluated by enzyme-linked immunospot (ELISPOT) assay. As control, response to RD1 proteins was included. Results were correlated with immune, microbiological and virological data. Results Among patients with active TB, 2/20 were excluded from the analysis, one due to cell artifacts and the other to unresponsiveness to M. tuberculosis antigens. Among those analyzable, response to selected RD1 peptides evaluated as spot-forming cells was significantly higher in subjects with active TB compared to those without (p = 0.02). Among the 12 TB patients studied over time a significant decrease (p =M. tuberculosis were negative. A ratio of RD1 peptides ELISPOT counts over CD4+ T-cell counts greater than 0.21 yielded 100% sensitivity and 80% specificity for active TB. Conversely, response to RD1 intact proteins was not statistically different between subjects with or without TB at the time of recruitment; however a ratio of RD1 proteins ELISPOT counts over CD4+ T-cell counts greater than 0.22 yielded 89% sensitivity and 70% specificity for active TB. Conclusion In this pilot study the response to selected RD1 peptides is associated with TB disease in HIV-infected individuals in a high TB endemic country. This response decreases after successful therapy. The potential of the novel approach of relating ELISPOT spot-forming cell number and CD4+ T-cell count may improve the possibility of diagnosing active TB and deserves further evaluation.</p
Expression of markers of immune activation on central and effector memory CD4 and CD8 T cells in PFMC.
<p>Expression of activation markers (HLADR/CD38, CCR5, CD69) was assessed on central memory (Tcm) (<b>A</b> and <b>C</b>) and effector memory (Tem) (<b>B</b> and <b>D</b>) for CD4 (<b>A</b> and <b>B</b>) and CD8 (<b>C</b> and <b>D</b>) in PBMC and PFMC T cells from HIV/TB co-infected subjects. **, p <b><</b> 0.01 and ***, p < 0.001</p
Immune Activation at Sites of HIV/TB Co-Infection Contributes to the Pathogenesis of HIV-1 Disease
<div><p>Systemic immune activation is critical to the pathogenesis of HIV-1 disease, and is accentuated in HIV/TB co-infected patients. The contribution of immune activation at sites of HIV/TB co-infection to viral activity, CD4 T cell count, and productive HIV-1 infection remain unclear. In this study, we measured markers of immune activation both in pleural fluid and plasma, and in T cells in pleural fluid mononuclear cell (PFMC) and peripheral blood mononuclear cell (PBMC) in HIV/TB co-infected subjects. The relationship between soluble and T cell activation markers with viral load in pleural fluid and blood CD4 T cell count were assessed. The T cell phenotype and activation status of HIV-1 p24 + T cells in PFMC and PBMC from HIV/TB patients were determined. We found that T cell and macrophage-specific and non-specific soluble markers of immune activation, sCD27, sCD163, IL1Ra, and sCD14, were higher in pleural fluid as compared to plasma from HIV/TB co-infected subjects, and higher as compared to pleural fluid from TB mono-infected subjects. Intestinal fatty acid-binding protein, a marker of intestinal tract damage, in plasma from HIV/TB co-infected patients was not different than that in HIV+ subjects. Expression of HLADR and CD38 double positive (HLADR/CD38) on CD4 T cells, and CD69+ on CD8 T cells correlated with pleural fluid viral load, and inversely with blood CD4 T cell count. Higher expression of HLADR/CD38 and CCR5 on CD4 T cells, and HLADR/CD38 and CD69 on CD8 T cells in PFMC were limited to effector memory populations. HIV-1 p24+ CD8 negative (includes CD4 + and double negative T cells) effector memory T cells in PFMC had higher expression of HLADR/CD38, Ki67, and CCR5 compared to HIV-1 p24- CD8 negative PFMC. Cumulatively, these data indicate that sites of HIV/TB co-infection are the source of intense immune activation.</p></div
IFABP in HIV/TB subjects with pleural TB.
<p>IFABP levels were measured in pleural fluid (PF) and plasma (PL) from HIV/TB co-infected patients, and in PL from CD4-matched HIV-1 infected (HIV) and HIV-1 un-infected healthy (HC) subjects.</p
Soluble Markers of immune activation at sites of HIV/TB co-infection.
<p>Plasma (PL) and Pleural fluid (PF) from HIV/TB co-infected subjects were assessed for soluble activation markers and compared to PL from HIV-1 infected and PF from TB mono-infected subjects. (<b>A</b>) sCD14 levels in PL and PF, (<b>B</b>) sCD14 correlation between PF and PL, (<b>C</b>) sCD163 and (<b>D</b>) sCD27 levels in PL and PF. **, p <b><</b> 0.01 and ***, p < 0.001</p
Expression of markers of immune activation and proliferation on CD4 and CD8 T cells at sites of HIV/TB, and association with HIV viral load in pleural fluid and CD4 T cell counts.
<p>Markers of immune activation and proliferation were assessed on PFMC T cells as compared to PBMC from HIV/TB co-infected subjects, and between PFMC from HIV/TB and TB mono-infected subjects. Analysis of CD4+ (<b>A</b>) and CD8+ (<b>B</b>)T cells are shown. Association of HLADR/CD38 on PFMC CD4 (<b>C and E</b>) and CD69 on PFMC CD8 (<b>D and F</b>) T cells with HIV viral load in pleural fluid (PF) <b>(C and D)</b> and blood CD4 T cell count (<b>E and F</b>). *, p< 0.05; **, p< 0.01 and ***, p<b><</b> 0.001.</p